Reversal of startle gating deficits in transgenic mice overexpressing corticotropin-releasing factor by antipsychotic drugs

Neuropsychopharmacology

Volumn 28, Issue 10, 2003, Pages 1790-1798

  Dirks, Anneloes ^a   Groenink, Lucianne ^a   Westphal, Koen G C ^a   Olivier, Jocelien D A ^a   Verdouw, P Monika ^a   Van Der Gugten, Jan ^a   Geyer, Mark A ^b   Olivier, Berend ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acoustic startle; Antipsychotics; CRF; CRH; Prepulse inhibition; Sensorimotor gating

Indexed keywords

CHLORDIAZEPOXIDE; CLOZAPINE; CORTICOTROPIN RELEASING FACTOR; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; GENE OVEREXPRESSION; GENOTYPE; MAJOR DEPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; STARTLE REFLEX; TRANSGENIC MOUSE; WILD TYPE; ACOUSTIC REFLEX; ANIMAL; ANIMAL BEHAVIOR; AUDITORY STIMULATION; BIOSYNTHESIS; BODY WEIGHT; COMPARATIVE STUDY; DEPRESSION; DISEASE MODEL; DOSE RESPONSE; GENETICS; INHIBITION (PSYCHOLOGY); MALE; MOUSE STRAIN; PHYSIOLOGY; STIMULATION;

ACOUSTIC STIMULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BODY WEIGHT; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INHIBITION (PSYCHOLOGY); MALE; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; REFLEX, ACOUSTIC; STARTLE REACTION; STIMULATION, CHEMICAL;

EID: 0642308244     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300256     Document Type: Article

References (58)

1. Aigner L, Arber S, Kapfhammer JP, Laux T, Schneider C, Botteri F et al (1995). Overexpression of the neural growth-associated protein GAP-43 induces nerve sprouting in the adult nervous system of transgenic mice. Cell 83: 269-278.
2. Anton RF (1987). Urinary free cortisol in psychotic depression. Biol Psychiatry 22: 24-34.
3. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999). The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160: 1-12.
4. Belanoff JK, Kalehzan M, Sund B, Fleming Ficek SK, Schatzberg AF (2001). Cortisol activity and cognitive changes in psychotic major depression. Am J Psychiatry 158: 1612-1616.
5. Braff DL, Geyer MA (1990). Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47: 181-188.
6. Braff DL, Geyer MA, Swerdlow NR (2001). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156: 234-258.
7. Braff DL, Grillon C, Geyer MA (1992). Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 49: 206-215.
8. Braff DL, Stone C, Callaway E, Geyer MA, Glick I, Bali L (1978). Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15: 339-343.
9. Carlson S, Willott JF (1996). The behavioral salience of tones as indicated by prepulse inhibition of the startle response: relationship to hearing loss and central neural plasticity in C57BL/6J mice. Hear Res 99: 168-175.
10. Conti LH, Murry JD, Ruiz MA, Printz MP (2002). Effects of corticotropin-releasing factor on prepulse inhibition of the acoustic startle response in two rat strains. Psychopharmacology 161: 296-303.
11. Dirks A, Groenink L, Bouwknecht JA, Hijzen TH, van der Gugten J, Ronken E et al (2002b). Overexpression of corticotropin-releasing hormone in transgenic mice and chronic stress-like autonomic and physiological alterations. Eur J Neurosci 16: 1751-1760.
12. Dirks A, Groenink L, Iutje Schipholt M, van der Gugten J, Hijzen TH, Geyer MA et al (2002a). Reduced startle reactivity and plasticity in transgenic mice overexpressing corticotropin-releasing hormone. Biol Psychiatry 51: 583-590.
13. 1A receptor knockout mice, show reduced startle reactivity and footshock-induced sensitization, as measured with the acoustic startle response. Behav Brain Res 118: 169-178.
14. Dulawa SC, Geyer MA (2000). Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice. Neuropharmacology 39: 2170-2179.
15. Dulawa SC, Scearce-Levie K, Hen R, Geyer MA (2000). Serotonin releasers increase prepulse inhibition in serotonin 1B knockout mice. Psychopharmacology (Berl) 149: 306-312.
16. Dunn AJ, Berridge CW (1990). Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev 15: 71-100.
17. Ellenbroek BA, Cools AR (1998). The neurodevelopmental hypothesis of schizophrenia: clinical evidence and animal models. Neurosci Res Commun 22: 127-136.
18. Ellenbroek BA, van den Kroonenberg PT, Cools AR (1998). The effects of an early stressful life event on sensorimotor gating in adult rats. Schizophr Res 30: 251-260.
19. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156: 117-154.
20. Geyer MA, Wilkinson LS, Humby T, Robbins TW (1993). Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol Psychiatry 34: 361-372.
21. Graham FK (1975). The more or less startling effects of weak prestimulation. Psychophysiology 12: 238-248.
22. Groenink L, Dirks A, Verdouw PM, Iutje Schipholt M, Veening JG, van der Gugten J et al (2002). HPA-axis dysregulation in mice overexpressing corticotropin-releasing-hormone. Biol Psychiatry 51: 875-881.
23. Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM (2003). International union of pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev 55: 21-26.
24. Hoffman DC, Donovan H (1995). Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) 120: 128-133.
25. Holsboer F (1999). The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 33: 181-214.
26. Kanes SJ, Hitzemann BA, Hitzemann RJ (1993). On the relationship between D2 receptor density and neuroleptic-induced catalepsy among eight inbred strains of mice. J Pharmacol Exp Ther 267: 538-547.
27. Koch M (1999). The neurobiology of startle. Prog Neurobiol 59: 107-128.
28. Koob GF, Heinrichs SC (1999). A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res 848: 141-152.
29. Koob GF, Heinrichs SC, Merlo Pich E, Menzaghi F, Baldwin HA, Miczek KA et al (1993). The role of corticotropin-releasing factor in behavioural responses to stress. Ciba Found Symp 172: 277-295.
30. Kumari V, Sharma T (2002). Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research. Psychopharmacology 162: 97-101.
31. Kumari V, Soni W, Sharma T (2002). Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics. Schizophr Res 55: 139-146.
32. Le Pen G, Moreau JL (2002). Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia. Reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology 27: 1-11.
33. Lipska BK, Weinberger DR (2000). To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23: 223-239.
34. Ludewig S, Ludewig K (2003). No prepulse inhibition deficits in patients with unipolar depression. Depress Anxiety 17: 224-225.
35. Lüthi A, van der Putten H, Botteri FM, Mansuy IM, Meins M, Frey U et al (1997). Endogenous serine protease inhibitor modulates epileptic activity and hippocampal long-term potentiation. J Neurosci 17: 4688-4699.
36. Mansbach RS, Geyer MA, Braff DL (1988). Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berl) 94: 507-514.
37. McCaughran Jr J, Mahjubi E, Decena E, Hitzemann R (1997). Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition. Psychopharmacology (Berl) 134: 131-139.
38. Meyer SE, Chrousos GP, Gold PW (2001). Major depression and the stress system: a life span perspective. Dev Psychopathol 13: 565-580.
39. Miller DD (2000). Review and management of clozapine side effects. J Clin Psychiatry 61(Suppl 8): 14-17.
40. Mitchell AJ (1998). The role of corticotropin releasing factor in depressive illness: a critical review. Neurosci Biobehav Rev 22: 635-651.
41. Moechars D, Lorent K, De Strooper B, Dewachter I, van Leuven F (1996). Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J 15: 1265-1274.
42. Morris R, Grosveld F (1989). Expression of Thy-1 in the nervous system of the rat and mouse. Immunol Ser 45: 121-148.
43. Olivier B, Leahy C, Mullen T, Paylor R, Groppi VE, Sarnyai Z et al (2001). The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics? Psychopharmacology (Berl) 156: 284-290.
44. Ouagazzal AM, Jenck F, Moreau JL (2001). Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity? Psychopharmacology 156: 273-283.
45. Owens MJ, Nemeroff CB (1991). Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43: 425-473.
46. Parham K, Willott JF (1988). Acoustic startle response in young and aging C57BL/6J and CBA/J mice. Behav Neurosci 102: 881-886.
47. Paylor R, Crawley JN (1997). Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology 132: 169-180.
48. Rigdon GC, Norman MH, Cooper BR, Howard JL, Boncek VM, Faison WL et al (1996). 1192U90 in animal tests that predict antipsychotic efficacy, anxiolysis, and extrapyramidal side effects. Neuropsychopharmacology 15: 231-242.
49. Schatzberg AF, Posener JA, DeBattista C, Kalehzan BM, Rothschild AJ, Shear PK (2000). Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. Am J Psychiatry 157: 1095-1100.
50. Schatzberg AF, Rothschild AJ (1992). Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry 149: 733-745.
51. Swerdlow NR, Martinez ZA, Hanlon FM, Platten A, Farid M, Auerbach P et al (2000). Toward understanding the biology of a complex phenotype: rat strain and substrain differences in the sensorimotor gating-disruptive effects of dopamine agonists. J Neurosci 20: 4325-4336.
52. Thompson RC, Seasholtz AF, Herbert E (1987). Rat corticotropin-releasing hormone gene: sequence and tissue-specific expression. Mol Endocrinol 1: 363-370.
53. Vasey MW, Thayer JF (1987). The continuing problem of false positives in repeated measures ANOVA in psychophysiology: a multivariate solution. Psychophysiology 24: 479-486.
54. Vidal M, Morris R, Grosveld F, Spanopoulou E (1990). Tissue-specific control elements of the Thy-1 gene. EMBO J 9: 833-840.
55. 2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25: 633-641.
56. Wheeler Vega JA, Mortimer AM, Tyson PJ (2000). Somatic treatment of psychotic depression: review and recommendations for practice. J Clin Psychopharmacol 20: 504-519.
57. Wiessner C, Allegrini PR, Rupalla K, Sauer D, Oltersdorf T, McGregor AL et al (1999). Neuron-specific transgene expression of Bcl-XL but not Bcl-2 genes reduced lesion size after permanent middle cerebral artery occlusion in mice. Neurosci Lett 268: 119-122.
58. Willott JF, Carlson S, Chen H (1994). Prepulse inhibition of the startle response in mice: relationship to hearing loss and auditory system plasticity. Behav Neurosci 108: 703-713.